TD Asset Management’s Stemline Therapeutics STML Stock Holding History
Bought
Maintained
Sold
Other funds holding STML
TD Asset Management's STML Position: Q3 2019 in Review
TD Asset Management sold out of Stemline Therapeutics (STML) in Q3 2019, closing a stake of 38,494 shares — an estimated $590K sold.
TD Asset Management first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $856K in Q3 2013. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.
- TD Asset Management reported no remaining Stemline Therapeutics position as of Q3 2019 after selling out during the quarter.
- TD Asset Management sold 38,494 Stemline Therapeutics shares in Q3 2019, an estimated $590K.
- TD Asset Management first reported a position in Stemline Therapeutics in Q2 2013 and held it in 6 quarters.
- TD Asset Management's Stemline Therapeutics position peaked at $856K in Q3 2013.
- 100 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q3 2019.
Based on TD Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.